In situ delivery of tumor-associated antigen (TAA) genes into dendritic cells (DC) has great potential as a generally applicable tumor vaccination approach. Although adenoviruses (Ad) are an attractive vaccine vehicle in this regard, Ad-mediated transduction of DC is hampered by the lack of expression of the Ad receptor CAR on the DC cell surface. DC activation also requires interaction of CD40 with its ligand CD40L to generate protective T cell-mediated tumor immunity. Therefore, to create a strategy to target Ad to DC in vivo, we constructed a bispecific adaptor molecule with the CAR ectodomain linked to the CD40L extracellular domain via a trimerization motif (CFm40L). By targeting Ad to CD40 using CFm40L, we 
Introduction
Melanoma vaccines based on ex vivo prepared autologous Dendritic Cells (DC) have been reported to induce specific T cell responses which in some cases were associated with improved survival (1) (2) (3) . In spite of its first clinical successes, serious draw-backs are inherent to this approach. The ex vivo culture and antigen-loading of DC according to cGMP guidelines and on a per-patient basis are laborious, time-consuming, and introduce inter-donor variability that may complicate the interpretation of clinical outcome. Furthermore, ex vivo modified DC migrate poorly in vivo, affecting the efficacy of the vaccine (4) . In vivo targeting of tumor-associated antigens (TAA) and/or activating agents to DC presents an attractive alternative (5) . The approaches used for in vivo targeting of antigens to DC range from viral or liposomal targeting to the conjugation of antigens directly to DC-binding ligands or mAbs (5, 6) , (7) (8) (9) (10) (11) (12) . Targeting of DC receptors such as DC-SIGN (13) , and CD11c (9) required the incorporation of additional DC maturation stimuli such as CD40L or Toll-Like Receptor-Ligands (TLR-L) to induce potent anti-tumor immune responses. Alternatively, DCtargeting motifs that simultaneously effect maturation induction may be used, such as the TLR4-binding Extra Domain A of fibronectin (14) or CD40L. Indeed, our in vitro and in situ studies have shown that the genetic targeting of antigens to the CD40 receptor efficiently and selectively delivers antigens to both human and murine DC and simultaneously induces their stable maturation, obviating the need for additional maturation stimuli for proper T cell activation (15) (16) (17) . Genetic targeting of TAA ensures durable presentation through MHC-I to specific cytotoxic T lymphocytes (CTL) (18) . Adenoviruses (Ad) are attractive vaccine vehicles as they are easily grown to high titers, exhibit low cytotoxicity, have a large cloning capacity, and display high-efficiency gene transfer, even to non-dividing target cells (19, 20) .
Moreover, modification of the capsid hexon motif has been shown to abolish the neutralizing effects of pre-existent humoral immunity to the commonly used Ad type-5 (Ad5) vector, thus 4 widening its therapeutic window and opening the possibility to use it for both priming and boosting (21) . Unfortunately, DC are relatively resistant to infection with Ad5 due to their lack of expression of the primary Ad5 receptor, Coxsackie-Adenovirus Receptor (CAR) (22) .
We previously showed that this limitation could be overcome by re-targeting Ad5 to CD40 using bispecific adaptor molecules that simultaneously neutralized the Ad5 fiber knob and agonistically bound CD40 on the DC surface (16, 23) . This approach facilitated the induction of T cell-mediated immune responses against non-self transgene products (17, 24) and protected mice from tumor growth through vaccination with ex vivo modified DC (17) .
However, the capacity of this approach to induce effective immune responses against poorly immunogenic TAA by targeted delivery to DC in vivo, being its most promising application,
has not yet been evaluated.
Melanoma antigens such as tyrosinase-related proteins 1 and 2 (TRP-1/-2] and gp100, are non-mutated auto-antigens (25, 26) to which T cell tolerance prevails (27) , eliciting only low-avidity CD8 + T cells due to thymic or extrathymic deletion of high-avidity autoreactive T cell clones (28) . Targeted in vivo delivery of TAA to DC may break this tolerance (5).
Moreover, agonistic binding of CD40 has been pinpointed as a vital mode of DC maturation to facilitate the induction of TAA-specific CTL (29) , thus providing a clear rationale for CD40-mediated DC targeting of Ad-based tumor vaccines. Here, we show that in vivo delivery through the skin of a CD40-targeted Ad5 vector leads to selective in vivo transduction of DC in the skin and injection site-draining lymph nodes (LN), resulting in increased CD8 + T cell responsiveness and enhanced therapeutic efficacy in the murine B16F10 melanoma model. 
Materials and Methods

Animals and cell lines
Peptides
The H-2K b -binding peptides SVYDFFVWL (TRP2 aa180-188 , derived from the murine melanosomal protein TRP2), ICPMYARV (ȕgal aa497-504 , derived from Escherichia coli ȕ-galactosidase) and the H2-D b -binding peptide KVPRNQDWL (gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] derived from the human melanasomal protein gp100 (30) were purchased from Leiden University Medical
Center, The Netherlands.
Ad vectors
The following replication defective, E1-substituted and E3-deleted Ad5 vectors were used: 1) Ad-GFP, encoding enhanced green fluorescent protein (eGFP) (31), 2) Ad-gp100, encoding full-length human gp100 (32) , and 3) Ad-GFP-TRP2 aa180-188 , encoding the (33) . These Ad vectors were propagated, titered and stored as described previously (34) .
Recombinant CFm40L adaptor protein
A recombinant molecular adaptor protein consisting of the soluble ectodomain of CAR linked to the ectodomain of mouse CD40 ligand via a trimerzation motif (CFm40L) was constructed, produced and purified as described previously (23) . CD40-Ad-GFP-TRP2 aa180-188 , CD40-Ad-gp100 or CD40-Ad-GFP (i.e.CD40-targeted Ad) were prepared by pre-incubating 3.125ȝg of CFm40L with 60 x 10 6 viral particles (vp) (600vp/cell) of Ad-GFP-TRP2 aa180-188 , Ad-gp100 or Ad-GFP for 30 min in 10-20ȝl of serum free medium at room temperature (RT).
Bone marrow-derived DC, skin DC and Ad infections
Bone Marrow-derived DC (BMDC) were generated as described previously by Samsom et al. (35) and were used for Ad infections. Murine ears were collected from sacrificed C57BL/6 mice and washed in 70% alcohol. The dorsal and ventral halves of the ears were separated mechanically and dorsal halves were cultured in 24-well plates in RPMI complete medium for 48 h at 37 o C. Migrated DC were harvested and used for Ad infections as described below.
DC were seeded at a density of 0.5 x 10 6 cells/well in a 24-well plate in 500ȝl serum free medium and were transduced with CD40-targeted-or untargeted-Ad-GFP or Ad-GFP-TRP2 aa180-188 at 37 o C for 2 h at a multiplicity of infection (MOI) of 600 based on vp. After 2 h of incubation, 2 ml of serum containing IMDM was added. Transduced DC were harvested after 48h, washed repeatedly and used for either flowcytometric analysis or vaccination. 
IFN-Ȗ intracellular staining
The IFN-Ȗ intracellular staining (ICS) assay was carried out to detect TRP2 aa180-188 and gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] specific T cells in mouse PBMC or splenocytes, as described previously (34) .
Isolation and Ad transduction of murine LN cells and splenocytes
LN and spleen were harvested from mice and single cell suspensions were made by chopping the tissues with scissors and gently pressing them through 100ȝm filters (BD Biosciences). Finally, the LN and spleen cells were washed twice in serum free medium, counted, and seeded at a density of 1x10 6 cells/well of 24-well plates in 500ȝl serum free medium. Cells were infected with Ad-GFP or CD40-Ad-GFP at an MOI of 300 (vp, calculated based on the DC numbers) for 2h at 37 o C. After infection, 2 ml of IMDM complete medium was added and the cells were cultured for 2 days. Subsequently, cells were harvested, washed, labeled with PE-labeled anti-MHC II (eBioscience) and/or anti-B220, and/or APClabeled anti-CD11c and appropriate isotype control antibodies (BD Biosciences), and subjected to flowcytometric analysis. In vitro antigen presentation assay BMDC or DC in LN suspensions were transduced with CD40-targeted-or untargetedAd vectors encoding GFP or TRP2 aa180-188 fused to GFP. Transgene-expressing DC were plated in round-bottom 96 well plates (Greiner Bio-one) with splenocytes containing previously primed TRP2 aa180-188 -specific CD8 + T cells, isolated from mice vaccinated with
Ad-GFP-TRP2 aa180-188 , at a ratio of 1:10. Splenocytes stimulated with DC loaded with TRP2 aa180-188 or ȕgal aa497-504 peptides were used as controls. After overnight stimulation, the percentage of CD8 + T cell producing intracellular IFN-Ȗ was determined by flow cytometry as described previously (34) .
Imaging and quantification of transgene expression in vivo
Transgenic GFP expression levels at the site of vaccination and in vaccination site Slides were brought to RT and placed in PBS for 5 min to remove OCT; endogenous biotin was blocked (DAKO Corporation) and slides were stained with biotinylated anti-IA/IE or anti-CD11c mAbs (BD Pharmingen). Specific binding of the antibody was detected using Cy3-conjugated streptavidine (Invitrogen). DAPI (Molecular probes) was used to stain nuclei and slides were mounted using mounting medium (Immunoconcepts NA Ltd). Staining was evaluated by fluorescence microscopy (Nikon instruments BV, The Netherlands) using appropriate filters.
Statistical analysis
Data was analyzed using one-way ANOVA with Bonferroni correction using GraphPad-Prism software. 
Results
Enhanced in vitro transduction and maturation of BMDC by CD40-Ad and enhanced prophylactic vaccination efficacy
BMDC were more efficiently transduced by CD40-Ad than by untargeted-Ad as determined by GFP transgene expression (Fig. 1A) and simultaneously underwent maturation as determined by expression levels of the DC maturation markers MHC-II and CD86 (Fig. 1B) .
To compare the anti-tumor efficacy of CD40-Ad and untargeted-Ad, we used the aggressive and poorly immunogenic murine B16F10 melanoma model (38) . Mice were vaccinated with syngeneic BMDC transduced in vitro by CD40-targeted-or untargeted-Ad-GFP-TRP2 aa180-188 .
Animals were subsequently inoculated s.c. with B16F10 cells on the distant flank (see Fig. 1C for a schedule of the experiment). BMDC transduced by CD40-Ad-GFP-TRP2 aa180-188 exhibited superior vaccination efficacy over BMDC transduced with Ad-GFP-TRP2 aa180-188 (Fig. 1D,E) and induced stronger TRP2 aa180-188 -specific CD8 + T cell responses in peripheral blood (Fig. 1D ).
Enhanced DC transduction and MHC-I mediated presentation of transgenic antigens through CD40-targeted transduction of DC in LN suspensions
To ascertain the ability of CD40-Ad to target and transduce tissue-derived DC, we performed in vitro experiments with skin-derived DC as well as with LN and spleen suspensions.
Although transduction levels were low, CD40-mediated Ad infection significantly improved the transduction efficiency of CD11c + DC migrated from murine ear skin explants ( Fig. 2A) .
As CD40 expression is not exclusively restricted to DC, we evaluated the tropism of CD40-Ad in single-cell suspensions of murine LN and spleen. CD40-Ad very efficiently and 
selectively transduced DC, identified as CD11c and MHC II double positive cells, but not B220 + B cells, in both LN and spleen single-cell suspensions ( Fig. 2A) .
To test whether DC in LN suspensions, transduced by CD40-Ad, presented endogenously synthesized and processed transgene-encoded antigens more efficiently than untargeted-Ad-transduced DC, we assessed the in vitro antigen presentation efficiency of LN samples transduced either by CD40-targeted-or untargeted-Ad-GFP-TRP2 aa180-188 . Data presented in Fig. 2B show that LNDC transduction with a CD40-Ad vector encoding TRP2 aa180-188 and GFP led to the activation of higher rates of specific IFN-Ȗ producing CD8 + T cells in TRP2 aa180-188 -primed splenocytes than transduction with the untargeted vector, although this did not reach significance, likely due to background reactivity e.g. against GFP.
CD40 targeting of Ad in vivo dramatically reduces total transgene expression levels but results in more selective DC transduction
Re-targeting Ad to CD40 may reduce undue toxicity of Ad by blocking the naturally broad tropism of Ad vectors. To this end we assessed the in vivo GFP transgene expression at the site of vaccination and in excised draining LN, using bioluminescent imaging. Total transgene expression levels were significantly lower at the site of vaccination in mice injected with CD40-Ad compared to untargeted-Ad at 24h post-injection (Fig. 3A,B ).
Immunohistochemical and fluorescence microscopic examination revealed sparse transduction of DC at the skin injection site (Fig. 3C ). Comparable reduction in total transgene expression levels (Fig. 4A,B ) but more selective transduction of DC was also observed in the vaccination site-draining LN (Fig. 4C ). This indicates a drastic reduction in the number of transduced cells resulting from an effective block of the natural tropism of the Nevertheless, even in the presence of Ad-binding macrophages, small numbers of DC may be transduced by untargeted Ad and thus effect direct CTL priming. injected BMDC (Fig. 1D) . To assess the effect of CD40 targeting on the induction of immunity against weakly immunogenic TAA, subsequent experiments (see Fig.6A for the followed experimental schedule) were conducted with an Ad vector encoding a full-length TAA of clinical relevance, i.e. gp100. Importantly, CD40 targeting of Ad-gp100 significantly enhanced the induction of a gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] specific CD8 + T cell response (Fig. 6B ) and accordingly also enhanced the anti-tumor efficacy, both prophylactically (not shown) and, more importantly, therapeutically (Fig. 6C ). This also translated into an improved survival of tumor-bearing animals receiving a CD40-Ad-gp100 vaccine (Fig. 6D) . These results thus Consequently, a significantly improved therapeutic anti-tumor efficacy was observed for an intradermally delivered Ad-gp100 vaccine through CD40 targeting.
CD40-targeted intradermal delivery significantly improves the anti-tumor efficacy of an Ad5 vector encoding a full-length weakly immunogenic tumor antigen
The efficacy of ex vivo loaded DC, which are often used as cancer vaccines (43) 
DC but is also found in macrophages, B cells and epithelial cells, which are poorly equipped to prime an effective CTL response. DC in single-cell suspensions of murine LN and spleen were also selectively and more efficiently transduced by CD40-Ad than by untargeted-Ad, and displayed enhanced presentation of the transferred gene products in the context of MHC class I. Similarly, CD46-or CD80/CD86-targeted Ad vectors have been reported to selectively transduce DC despite high expression levels of these receptors on e.g. monocytes and B cells (48) . These differences in infection susceptibility may at least in part be attributed to the presence or absence of active endocytic pathways (49).
Our in vivo bioluminescent imaging data clearly showed that in vivo retargeting of Ad to CD40 almost completely ablated its natural tropism in both murine skin and skin-draining LN. 
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